![]()
|
|
||||||||
J. Biol. Chem., Vol. 277, Issue 16, 14005-14010, April 19, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the Department of Pharmacology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104
Received for publication, December 28, 2001
| |
ABSTRACT |
|---|
|
|
|---|
Histone acetylation by p300/CBP and PCAF
coactivators is considered to be a key mechanism of chromatin
modification and transcriptional regulation. A multiprotein cellular
complex, INHAT (inhibitor of acetyltransferases), containing the
Set/TAF-I Chromatin plays important structural and regulatory roles in the
control of gene expression in eukaryotes (1-4). It has been suggested
that the modulation of chromatin structure and transcription can be
achieved through the interaction between histones and
chromatin-remodeling factors and/or post-translational modifications of
N-terminal histone tails (2, 4-8).
Evidence is accumulating for the role of post-translational
modifications such as acetylation (1, 3, 9), phosphorylation (10-12),
and more recently methylation of N-terminal histone tails in
chromatin-linked processes, including transcription (13-16). One such
modification, which has been intensively studied, is acetylation of
lysine residues of histone tails. It is generally believed that
hypo/unacetylated histones associate with basal/repressed chromatin,
whereas hyperacetylation of histones has been linked to
transcriptionally active chromatin domains. Transcriptional coactivators such as
p300/CBP,1 PCAF, and ACTR
have intrinsic acetyltransferase activity, and it is proposed that
these coactivators contribute to transcription at least in part by
acetylating histones and nonhistone proteins (17-19). Given that
histone acetylation plays an important role in modulating
transcription, it is conceivable that the processes leading to histone
acetylation are regulated and that their misregulation by cellular and
viral proteins could have significant influences on chromatin
modification and gene expression (7, 20-26). Regulation of histone
acetylation has been shown to be mediated by activities that bind
either to the acetylases or the substrate histones. For example, while
E1A inhibits histone acetylation by directly binding to p300/CBP and
PCAF, RbAp 46/48 stimulates histone acetylation and transcription by
p300/CBP by directly binding to histones (22, 25, 27). Additionally,
although acetylation of histones by p300/CBP, PCAF, and ACTR promotes
transcription, acetylation of ACTR by p300/CBP destabilizes
interactions between nuclear receptors and ACTR, resulting in
attenuation of hormonal signaling (28). Therefore, protein acetylation
may have both positive and negative regulatory roles in transcription.
While investigating the cellular regulation of HAT activity of
coactivators, we reported the identification of a cellular complex
termed INHAT (inhibitor of acetyltransferases). INHAT binds to histones
and inhibits p300/CBP- and PCAF-mediated histone acetylation. We
referred to this mechanism as histone-masking (7). INHAT is a
multiprotein complex with the putative oncoprotein Set/TAF-I Among the subunits, pp32 belongs to a family of acidic leucine-rich
nuclear proteins that includes April, LANP, PHAP1, and Mapmodulin
(29-33). Along with other INHAT subunits, pp32 is also a subunit of
the RNA transport pathway (34). Additionally, LANP was shown to
associate with ataxin-1, although the significance of that interaction
is unclear (35). pp32 has also been reported to suppress cell
transformation induced by multiple oncogenes, including Ras and Myc
(30, 36). Like Set/TAF-I In this report, we have analyzed the HAT inhibitory characteristics of
INHAT subunits with emphasis on pp32. We show that the INHAT complex
and each of its subunits show overlapping but distinct specificities in
their HAT inhibitory activity by targeting different histone subunits.
The colocalization studies show that although the full-length pp32
colocalizes with distinct histone domains in the nucleus, a mutant pp32
defective in HAT inhibition and histone binding fails to colocalize
with histones, indicating that histone binding is a prerequisite for
pp32 function in the regulation of histone acetylation and transcription.
Plasmids and Proteins--
For bacterial and eukaryotic
expression constructs of Set/TAF-I HAT Assay--
Histone and nucleosome acetyltransferase assays
were performed as described previously (7).
In Vitro Immunoprecipitation and Interaction
Assays--
[35S]methionine-labeled INHAT subunits and
pp32-deletion mutant proteins were generated by in vitro
transcription/translation and used in histone binding and
immunoprecipitation assays as described (7). For histone binding
specificities of INHAT subunits, individual histones were used for each
assay instead of total histones.
Transfection Assays--
CV-1 cells were seeded at 20,000 cells/well of a 48-well dish as described (7) with internal control
pRLSV40 (5 ng) and MH100-TK-LUC (100 ng) as reporter. CMXGal4·CBP
(200 ng) and CMXRHN·pp32 derivatives (100 and 50 ng) used for Fig. 6
were added where indicated. The amount of DNA in each transfection was
kept constant by addition of pCDNA3 vector. The results in Fig. 6
are representative of three independent experiments. The margin of
error was less than 10% between the mean values of each assay.
Peptides--
The pp32 peptide (residues 150-180) was
synthesized commercially (Annovis, Aston, PA). Product purity was
greater than 85%, and the molecular weight of synthesized peptide was
confirmed by mass spectrometry analysis.
Immunostaining--
For endogenous pp32 detection, NIH3T3 cells
seeded in 35-mm2 plate were fixed and incubated with
anti-pp32 antibodies and immunocytostained with secondary antibody
conjugated with FITC (Jackson ImmunoResearch Laboratories). NIH3T3
cells were seeded overnight and transiently transfected with
pEGFP·C1-INHAT subunits and pEGFP-C1-pp32-C2 as indicated. After
24 h, cells were washed with phosphate-buffered saline and fixed
in 50% acetone/methanol. For histone staining, cells were incubated
with antihistone antibodies (Chemicon International), followed by
incubation with Cy3-conjugated anti-mouse IgG (Jackson ImmunoResearch
Laboratories). For nucleus detection, cells were incubated with DAPI
(Molecular Probes) stain and mounted with Gel/Mount. Slides were
examined under oil immersion with a confocal microscope with Bio-Rad
1024-ES using the Confocal AssistantTM program and Nikon
Eclipse E-600 with X60 objectives. Raw data images were processed
further using the Confocal AssistantTM program.
Specificity of Inhibition of Histone Acetylation by
pp32--
Using baculovirus-expressed FLAG-tagged p300, PCAF, and pp32
purified as GST fusion proteins from Escherichia coli, we
tested the ability of pp32 to inhibit histone and nucleosome
acetylation. In agreement with previous results, the acetylation of
core histones by p300 and PCAF was inhibited by addition of saturating
concentrations of pp32 (Fig. 1, compare
lanes 1 and 3 to lanes 2 and
4, respectively). Additionally, nucleosomal histone
acetylation by p300 and PCAF was also inhibited by pp32 (data not
shown). No proteolytic degradation of histones in the presence of pp32
was evident (Fig. 1, Coomassie and data not shown). These
observations demonstrate that pp32 inhibits histone acetylation and
prompted us to finely map the HAT inhibitory domain(s) of pp32.
Mapping of the pp32 INHAT Domain--
pp32 contains previously
characterized structural domains, including a highly acidic C-terminal
domain homologous to that of TAF-I (amino acids 167-249), an
A series of pp32 N-terminal deletion mutant proteins was also generated
and tested for the ability to inhibit histone acetylation. It is
interesting that the deletion of the first 1-59 residues of pp32
(pp32-N1, Construct 4) showed a slight increase
in INHAT activity when compared with that of the full-length pp32. This suggests the possible existence of a negative autoregulatory domain in
the N terminus of pp32 (residues 1-59). The overall role of this
domain in pp32 activity in vivo remains to be determined. Consistent with the results of C-terminal deletion analysis, both pp32-N2 (Construct 5), which lacks residues 1-119, and
pp32-N3 (Construct 6), which lacks residues 1-149 of the N
terminus, showed strong HAT inhibitory activity. Although deletion of
residues 181-249 did not significantly affect the HAT inhibitory
activity of pp32-C1 (Construct 2), pp32-N5, which only
contains the C-terminal residues 190-249, still retained reasonably
strong INHAT activity (Construct 7). Thus, the removal of
amino acids 150-180 uncovered a direct role for the C-terminal acidic
domain of pp32 that is similar to the INHAT domain of Set/TAF-I
To directly test whether pp32 INHAT domain I functions independently in
inhibiting histone acetylation, a peptide covering the INHAT domain I
of pp32 (residues 150-180) was synthesized and analyzed in HAT assays.
A schematic diagram of pp32 illustrating the putative INHAT domain and
the amino acid composition of peptide pp32 is shown in Fig.
2B. The pp32 INHAT peptide strongly inhibited p300-mediated
acetylation of core histones (data not shown) and four individually
purified histone subunits in a dose-dependent manner (Fig.
2C). The relative IC50 values of this peptide
toward the individual histones H2B, H2A, H3, and H4 ranged between 0.6 and 1.5 µM (Fig. 2C). These results are
consistent with those obtained with purified full-length pp32 protein
and further directly implicate INHAT domain I, spanning amino acids
150-180, as a major determinant of the INHAT activity of pp32.
Histone Binding Specificity of pp32 and INHAT--
Histone and
chromatin binding activity of both TAF-I proteins has been previously
reported (37). Additionally, we have shown that the INHAT complex
associates with histones on chromatin in vivo and blocks
them from serving as acetylase substrates, implying a critical role for
histone binding in the INHAT-mediated inhibition of acetylation (7). To
determine whether HAT inhibitory properties of pp32 mutants correlate
with their histone binding characteristics, we compared the histone
binding properties of pp32 mutants.
In vitro immunoprecipitation experiments utilizing
radiolabeled full-length and mutant pp32 proteins with total histones
were carried out to determine the histone binding properties of pp32. pp32-C1, which retained histone acetylation inhibitory activity, was
efficiently immunoprecipitated with antihistone antibodies (Fig.
3A, lane 3) in a
manner similar to the histone binding properties of full-length pp32
(Fig. 3A, lane 8). Importantly, however, pp32-C2, which lacks INHAT domains I and II and had lost its HAT inhibitory activity (Fig. 2), did not bind to histones (Fig. 3A,
lane 6), providing a strong correlation between histone
binding and the HAT inhibitory activity of pp32. The N-terminal mutant
proteins were also tested for their histone binding ability, and as
predicted from their HAT inhibitory activity, all N-terminal mutants
tested bound to histones with comparable affinity (Fig. 3B,
lanes 3, 6, and 9). Together these
results suggest histone binding as a prerequisite for HAT inhibition by
pp32.
We also tested the hypothesis that pp32 and other INHAT subunits might
have distinct binding affinities toward different histone subunits. To
address this question of histone binding specificity, we analyzed the
binding properties of pp32 and the other INHAT subunits to individual
histones in vitro. For that purpose, radiolabeled full-length pp32 was incubated with each histone subunit separately and
immunoprecipitated with antihistone antibodies. The antihistone antibodies bound specifically to an antigenic determinant that is
present on all four histone subunits and pulled down approximately the
same amount of isolated histone subunits (data not shown). Histones H2B
and H3 showed stronger interaction with pp32 (Fig. 4, panel I). Analysis of
histone subunit binding by Set/TAF-I
To determine whether histone binding properties of INHAT and its
subunits correlate with the ability to inhibit individual histone
acetylation, the inhibitory activity of INHAT and its subunits toward
each histone subunit was titrated (Fig. 4B). In agreement
with the histone subunit binding properties of pp32 (Fig.
4A), inhibition of histone H2B acetylation by pp32 was
slightly higher than that of the other subunits (Fig. 4B,
panel pp32). Inhibition by purified Set/TAF-I Colocalization of INHAT Subunits with Histones--
The
observation that pp32 and other INHAT subunits associate with histones
in vitro led us to investigate whether they would individually colocalize with histones in vivo. We have
previously shown, using ChIP (chromatin immunoprecipitation) assays,
that INHAT forms a complex with histones in vivo (7).
Localization of endogenous pp32 was examined using anti-pp32 antibodies
and a secondary antibody conjugated with FITC. Next we generated
C-terminal GFP fusions of pp32, TAF-I
Endogenous pp32 was predominantly found in the nucleus, with some
cytoplasmic distribution (Fig.
5A, FITC-pp32). The
overlay and individual detection of endogenous pp32 and histones show both proteins are in the nucleus (Fig. 5A). In agreement
with the localization of endogenous pp32, GFP·pp32 was also detected mainly in the nucleus (Fig. 5, A and B,
FITC-pp32 and GFP·pp32), whereas
GFP·TAF-I
Our in vitro binding studies demonstrated that pp32-C2
failed to inhibit histone acetylation and did not bind to histones. We
utilized GFP·pp32-C2 in colocalization analysis to further demonstrate the interaction specificity between pp32 and histones in vivo. Like GFP·pp32, GFP·pp32-C2 localized in the
nucleus (Fig. 5C). However, in contrast to the GFP·pp32,
which showed extensive colocalization with histones (Fig.
5B, overlay), a dramatic reduction in
colocalization of GFP·pp32-C2 and histones, as judged by the decreased number of bright yellow speckles, was observed (Fig. 5C, overlay). These results again demonstrate the
specificity of the in vivo interactions between histones and
pp32. Taken together, these in vivo colocalization studies
are consistent with the hypothesis that the HAT inhibitory activity of
the individual INHAT subunits is accomplished through mechanisms that
at least in part involve histone binding.
pp32 Blocks HAT-dependent Transcription--
The
demonstration that HAT inhibition by pp32 occurs through histone
binding mediated by its INHAT domain implies that this domain may play
a regulatory role in HAT-mediated transcription. We and others have
shown that a Gal4 DNA binding domain fusion of CBP (Gal4·CBP:
1092-2002) activates transcription in a HAT-dependent manner (7, 38). Furthermore, we have shown that Gal4·CBP-mediated transcriptional activation was severely inhibited by the overexpression of Set/TAF-I In this study we have characterized differential HAT inhibitory
activity of the INHAT subunits with special emphasis on pp32 and have
proposed a role for INHAT in the maintenance of a basal/repressive chromatin state. We provide in vitro evidence demonstrating
that the INHAT complex and its individual subunits show distinct but overlapping histone target and HAT inhibition specificities and that
these properties may be regulated based on their physical existence in
free or complexed form with other subunits. In vivo colocalization and transcription studies suggest a role for the INHAT
domain of pp32 in histone binding, HAT inhibitory activity, and
transcriptional repression.
Using N- and C-terminal deletion mutagenesis, we show that pp32
contains two independent HAT inhibitory domains. Although the pp32
INHAT domain I maps between amino acids 150 and 180, pp32 INHAT domain
II, which is similar to the INHAT domain of TAF-I proteins, resides
between amino acids 190 and 249. Because the INHAT domain I overlaps
with the tumor suppressor domain, it will be important to determine in
the future whether the INHAT activity plays any role in this latter
property of pp32. In agreement with the HAT inhibitory properties, a
pp32 mutant defective in HAT inhibition also fails to bind histones,
suggesting that histone binding is an integral part of pp32-mediated
HAT inhibition. Although isolated pp32 binds to and inhibits
acetylation of histone H2B and H3 with high affinity, this H2B
preference is lost when pp32 is incorporated into the INHAT complex,
which predominantly binds to and inhibits acetylation of histones H3
and H4. These results are consistent with the distinct HAT inhibitory
properties of INHAT and its subunits and are quite remarkable in that
they suggest that the in vivo function of TAF-I Consistent with previous reports, our colocalization studies
demonstrate that pp32 is predominantly nuclear and show that it
associates with certain subnuclear domains of histones, suggesting the
pp32 and/or INHAT bind to selected sites on chromatin. Although the
identities of these sites have not been determined, it is possible that
pp32-targeted histones may represent repressed chromatin, and histone
domains free of pp32 and INHAT may indicate the active state of
chromatin. This in vivo binding of pp32 to histones is specific, because a pp32 mutant defective in HAT inhibition and in vitro histone binding demonstrated a significant
reduction in colocalization with histones in vivo.
When overexpressed, pp32 inhibits Gal4·CBP-mediated transactivation,
implicating a role for pp32 in regulating HAT-mediated transcriptional
events and suggesting a role for pp32 in the maintenance of the
basal/repressive state of genes. Based on the implication that
INHAT subunits are components of the basal/repressive state of genes,
we propose that the regulation of INHAT activity by cellular
mechanisms, which prevent their binding to histones, will play an
important role during activation of transcription.
In summary, our results describe overlapping but distinct HAT
inhibitory and histone binding properties of INHAT and its subunits. The recently proposed histone code hypothesis envisions that the level
and combination of epigenetic marking, including acetylation, methylation, and phosphorylation on histones, will play a fundamental role in chromatin-based processes, including transcription (2, 6). An extension of this hypothesis is that the epigenetic marking of histones (including acetylation) therefore should be regulated. Given that the histone code dictates the transition between
transcriptionally active and silent chromatin states, we propose that
INHAT and other yet to be identified parallel complexes will play a
significant role in the establishment and maintenance of the histone
code, reflecting the transcriptional off or on states of chromatin domains.
oncoprotein and pp32 strongly inhibits the HAT activity of
p300/CBP and PCAF by histone masking. Here we report that the INHAT
complex and its subunits have overlapping but distinct HAT inhibitory
and histone binding characteristics. We provide evidence suggesting that the histone binding and INHAT activity of pp32 can be regulated by
its physical association with other INHAT subunits. In vivo colocalization and transfection studies show that pp32 INHAT domains are responsible for histone binding, HAT inhibitory activity, and
repression of transcription. We propose that INHAT and its subunits may function by modulating histone acetyltransferases through
a histone-masking mechanism and may play important regulatory roles in
the establishment and maintenance of the newly proposed "histone
code" of chromatin.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
,
TAF-I
, and a nuclear protein, pp32, as the major subunits. We had
previously shown that Set inhibits HAT-mediated transcription when
overexpressed in intact cells. These results suggest that INHAT may
play a role in transcription by binding to histones. Although we have
previously characterized the role of Set/TAF-I
in regulation of
histone acetylation and transcription, very little is known about the
role of pp32 in HAT regulation and transcription.
and TAF-I
, pp32 also has a long
C-terminal acidic tail, indicating an evolutionary conserved role for
this domain in the function of these proteins. Besides their C-terminal
acidic domains, little is known about any common or distinct
characteristics of Set/TAF-I
and pp32 in HAT and transcriptional
regulation. Additionally, it is not clear how the activity of the
individual INHAT subunits contributes to the overall activity of the
complex and whether the activity of the subunits can be dictated based
on whether they are free or part of the complex.
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
, TAF-I
, pp32, CBP, and their
derivatives, the appropriate PCR-amplified fragments were cloned into
pGEX4T2, CMX-PL1, RHNCMX-PL1, CMXGAL4, and pEGFP-C1
(CLONTECH) vectors. Sequences of all constructs surrounding the cloning sites were verified by automated sequencing. Recombinant GST proteins were purified using glutathione beads (Amersham Biosciences). Purification of baculovirus-expressed FLAG-p300 and FLAG-PCAF was carried out as described (22). The INHAT
complex was purified from HeLa cells as described (7).
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (48K):
[in a new window]
Fig. 1.
Recombinant pp32 blocks p300- and
PCAF-mediated histone acetylation. Histones were incubated with
p300 and PCAF without (lanes 1 and 3) or with
pp32 (lanes 2 and 4) as indicated. Samples were
separated by SDS-PAGE and analyzed by phosphorimager. Positions of
individual histones H3, H2B, H2A, and H4 are shown. Coomassie Blue
staining of p300-HAT inhibition assay gel is shown.
-helical N-terminal domain (amino acids 1-206), and a central
domain containing the tumor suppressive activity that spans amino acids
150-174 (30, 36). We generated and purified a series of N- and
C-terminal deletion mutants of pp32 as GST fusion proteins and examined
their HAT inhibitory activity in order to identify the HAT inhibitory
domain(s) of pp32 (Fig. 2A).
Approximately the same amount of expressed mutant proteins was used for
the HAT inhibitory activity assay, and purified GST protein alone had
no effect on the assay system (data not shown). When compared with the
full-length protein (Construct 1), deletion of large parts
of the acidic C-terminal residues 181-249 of pp32 (pp32-C1,
Construct 2) overall had no effect on the INHAT activity.
However, further deletion of additional C-terminal sequences (residues
151-180) resulted in the loss of the entire inhibitory activity
(pp32-C2, Construct 3). Interestingly, this domain overlaps with the tumor suppressor domain of pp32 (36). These
results suggest that a major HAT inhibitory domain of pp32 resides
between amino acids 151 and 180.

View larger version (25K):
[in a new window]
Fig. 2.
Mapping of the pp32 INHAT domains.
A, recombinant wild type (Construct 1) and mutant
pp32 proteins (Constructs 2-7) were utilized in
p300-mediated acetylation assays of total histones. The pp32 INHAT
domains I and II are shown as two different striped boxes.
The C-terminal domain rich in acidic amino acids is indicated by a
two-headed arrow. B, sequence of the synthesized
pp32 peptide representing pp32 INHAT domain I is indicated as
peptide pp32: 150-180. The full-length pp32 protein is
shown in the upper panel with pp32 INHAT domains.
C, different concentrations of peptide pp32 were assayed for
their INHAT activities with individual histone subunits H2B and H2A
(left panel) and H3 and H4 (right panel) as
indicated.
and
TAF-I
in the inhibition of histone acetylation (7). Together, these
results putatively map the HAT inhibitory domains of pp32 at the C
terminus of the protein in two separable subdomains termed pp32 INHAT
domain I (residues 151-180) and domain II (residues 190-249).

View larger version (29K):
[in a new window]
Fig. 3.
Histone binding properties of pp32 correlate
with its INHAT function. In vitro radiolabeled
full-length pp32 (panel A, lane 7), pp32-C1
(panel A, lane 1), and pp32-C2 (panel
A, lane 4) were incubated with (panel A,
lanes 3, 6, and 8) or without
(panel A, lanes 2, 5, and
9) total histones and immunoprecipitated with antihistone
antibodies. Lanes 1, 4, and 7 of
panel A indicated 10% of the input. In vitro
radiolabeled pp32-N1, N2, and N3 were incubated with (panel
B, lanes 3, 6, and 9) or without
(panel B, lanes 2, 5, and
8) total histones and immunoprecipitated with antihistone
antibodies. Lanes 1, 4, and 7 of
panel B indicated 10% of the input.
demonstrated that this subunit
has the strongest affinity to histone H3 and histone H4 (Fig. 4,
panel II). TAF-I
bound with higher affinity to histones
H4 and H2B (Fig. 4, panel III). It is interesting that the
reconstituted INHAT complex, where all three INHAT subunits are
combined, showed stronger interactions with histones H3 and H4 (Fig. 4,
panel IV) and little interaction with histone H2B. Binding
to histone H2A was very low with all three individual subunits of the
INHAT complex. The above results indicate the INHAT complex displays a
histone binding property that is overall different from that of its
individual subunits. From these in vitro results we have
concluded that INHAT and its subunits have distinct but overlapping
histone binding properties, and we suggest that individual INHAT
activity of subunits may be regulated by their physical association
with other subunits.

View larger version (28K):
[in a new window]
Fig. 4.
Determination of histone binding
specificities of the INHAT subunits. A, the INHAT
subunits and complex have overlapping but distinct histone subunit
binding specificity. In vitro radiolabeled pp32,
Set/TAF-I
, and TAF-I
were incubated individually or as a
reconstituted complex with each individual histone subunit and
immunoprecipitated with antihistone antibodies. The percentage of each
binding relative to the strongest binding (arbitrarily set at 100%)
in each set of experiments was quantitated by the phosphorimager
ImageQuant program. The percent of binding numbers represent the mean
values of two independent experiments. The input represents 10% of the
materials used for immunoprecipitation. B, histone
specificity of inhibition by INHAT and its subunits. Increasing amounts
of purified pp32 (upper left panel) or Set/TAF-I
(upper right panel) and the INHAT complex (lower left
panel) were incubated separately with 500 ng of individual
histones H3, H4, H2A, and H2B prior to the addition of p300. Reaction
samples were separated by SDS-PAGE. The radioactivity of individual
histone bands was determined from the phosphorimager, and percent
activity remaining was calculated using the value of acetylation of
each histone in the absence of INHAT and its subunits as 100%.
protein was
very similar for all histone subunits, although it displayed a lower
binding affinity for histone H2B. However, the INHAT complex showed
slightly lower inhibitory activity toward histone H2B, in agreement
with its histone subunit binding properties. Together these results
indicate that INHAT and its individual subunits display distinct but
overlapping histone substrate preferences in vitro and that
the inhibition of histone acetylation specificity of INHAT subunits may
be regulated by their physical association with other subunits.
, and TAF-I
proteins and
carried out colocalization studies to demonstrate the association
between individual INHAT subunits and histones in intact cells. NIH3T3 cells transfected with expression constructs coding individual GFP-fused INHAT subunits were immunostained with antihistone antibodies and Cy3-conjugated secondary antibodies. They were DAPI stained and
analyzed by confocal fluorescence imaging microscopy. Intact histones
and nuclei were detected by anti-Cy3-histone antibodies and DAPI
staining, respectively.
and GFP·Set/TAF-I
exhibited both cytoplasmic and
nuclear staining (Fig. 5, D and E,
GFP·TAF-I
and
GFP·Set/TAF-I
) in our assay conditions. No
specific immunofluorescence signal was detected in the nuclei of NIH3T3
cells when primary antibodies were substituted with anti-mouse control
antibodies (data not shown). Based on the hypothesis that INHAT binds
to histones on chromatin, prevents them from being acetylated, and
serves as a component of the repressive/basal state of chromatin, one
would expect that under normal circumstances INHAT and histones would localize on some but not all chromatin domains. The overlay of staining
of endogenous as well as GFP·pp32 and histones showed colocalization
of pp32 and histones inside the cell nucleus. As expected, it
was also evident that a significant fraction of histones did not
colocalize with pp32 under these assay conditions, suggesting that the
histone-INHAT interaction is specific and implying that binding of
histones to pp32 may be regulated at different chromatin loci in the
nucleus. It remains to be determined whether pp32-histone colocalized
domains represent repressed/basal chromatin and whether histone domains
lacking pp32 represent the active state of chromatin. Although a
significant amount of TAF-I proteins displayed cytoplasmic localization, it nonetheless showed nuclear colocalization with histones at varying levels (Fig. 5, D and E).

View larger version (52K):
[in a new window]
Fig. 5.
Localization of INHAT subunits with
histones. Endogenous pp32 in NIH3T3 cells was detected by
immunocytostaining with anti-pp32 antibodies and FITC-conjugated
secondary antibodies (A, FITC-pp32). NIH3T3 cells
were transfected with constructs representing GFP·pp32
(B), GFP·pp32-C2 (C), GFP·TAF-I
(D), and Set/TAF-I
(E) fusion proteins. Cells
were immunocytostained with antihistone antibodies and Cy3-conjugated
secondary antibodies (Cy3-histones). The overlays of GFP
proteins and Cy3-stained histones are shown in all cases. DAPI staining
which detected the nuclei of cells is also shown.
in an INHAT domain-dependent manner
in vivo (7). To determine the effect of pp32 and its INHAT
domains on CBP-HAT-directed transcription, the Gal4·CBP (1092-2002)
construct was cotransfected with various pp32 constructs, and the
expression of the Gal4 responsive reporter gene was analyzed. The
Gal4·DBD fusion of CBP activated transcription as expected (Fig.
6, lane Gal4·CBP
and Ref. 7). This Gal4·CBP HAT-mediated transcription was severely
inhibited at varying degrees by all pp32 constructs tested except for
pp32-C2, which does not contain the INHAT domains (Fig. 6). These
overexpression studies imply a regulatory role for pp32 in HAT-mediated
transcription and suggest that pp32 may serve as a component of the
basal/repressive state of genes.

View larger version (18K):
[in a new window]
Fig. 6.
Overexpression of pp32 inhibits
HAT-dependent transactivation. Overexpression of pp32
inhibits CBP-HAT-dependent transcription. CV-1 cells were
transfected with the reporter pMH100-TK-Luc, Gal4·CBP (1092-2002),
and pp32 derivatives as indicated. Following transfection, cells were
grown for 48 h, and cell extracts were prepared and assayed for
luciferase activity. The percent reporter activity was determined
utilizing the values of luciferase activity of Gal4·CBP as
100%.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
,
Set/TAF-I
, and pp32 may well be determined by their existence either
as free proteins or as subunits of the INHAT complex. This prediction
becomes more relevant because the INHAT subunits have also been
purified in other biological contexts, either in free forms or as part
of a complex with other proteins (31, 33, 34, 39-41). The in vivo implication of these differential histone binding and HAT inhibitory properties of the INHAT subunits remains to be determined.
| |
ACKNOWLEDGEMENTS |
|---|
We thank Drs. B. Forman, I. Schulman, and S. Ghosh for critical reading of the manuscript. We are grateful to Drs. J. Steitz for anti-pp32 antibodies, B. Forman for CMXHisRHN vector, and the National Cell Culture Center (Minneapolis, MN) for large scale propagation of HeLa cells used in this study.
| |
FOOTNOTES |
|---|
* This work was supported by National Institutes of Health Grant RO1-DK57079 (to D. C.) and NIDDK, National Institutes of Health Grant P30-DK50306.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
To whom correspondence should be addressed: Dept. of Pharmacology,
University of Pennsylvania School of Medicine, Philadelphia, PA 19104. Fax: 215-573-9004; E-mail: debu@pharm.med.upenn.edu.
Published, JBC Papers in Press, February 5, 2002, DOI 10.1074/jbc.M112455200
| |
ABBREVIATIONS |
|---|
The abbreviations used are: CBP, CREB-binding protein; CREB, cAMP response element-binding protein; RbAp 46/48, Rb-associated protein 46/48; HAT, histone acetyltransferase; INHAT, inhibitor of acetyltransferases; GST, glutathione S-transferase; GFP, green fluorescent protein; DAPI, 4',6'-diamidino-2-phenylindole dihydrochloride; FITC, fluorescein isothiocyanate; PCAF, p300/CBP-associated factor; ACTR, activator of thyroid and retinoid receptors.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Grunstein, M.
(1997)
Nature
389,
349-352[CrossRef][Medline]
[Order article via Infotrieve] |
| 2. |
Strahl, B. D.,
and Allis, C. D.
(2000)
Nature
403,
41-45[CrossRef][Medline]
[Order article via Infotrieve] |
| 3. |
Struhl, K.
(1998)
Genes Dev.
12,
599-606 |
| 4. |
Fyodorov, D. V.,
and Kadonaga, J. T.
(2001)
Cell
106,
523-525[CrossRef][Medline]
[Order article via Infotrieve] |
| 5. |
Hassan, A. H.,
Neely, K. E.,
Vignali, M.,
Reese, J. C.,
and Workman, J. L.
(2001)
Front. Biosci.
6,
D1054-1064[Medline]
[Order article via Infotrieve] |
| 6. |
Jenuwein, T.,
and Allis, C. D.
(2001)
Science
293,
1074-1080 |
| 7. |
Seo, S. B.,
McNamara, P.,
Heo, S.,
Turner, A.,
Lane, W. S.,
and Chakravarti, D.
(2001)
Cell
104,
119-130[CrossRef][Medline]
[Order article via Infotrieve] |
| 8. |
Struhl, K.
(1999)
Cell
98,
1-4[CrossRef][Medline]
[Order article via Infotrieve] |
| 9. |
Bjorklund, S.,
Almouzni, G.,
Davidson, I.,
Nightingale, K. P.,
and Weiss, K.
(1999)
Cell
96,
759-767[CrossRef][Medline]
[Order article via Infotrieve] |
| 10. |
Lo, W. S.,
Duggan, L.,
Tolga, N. C.,
Emre,
Belotserkovskya, R.,
Lane, W. S.,
Shiekhattar, R.,
and Berger, S. L.
(2001)
Science
293,
1142-1146 |
| 11. |
Sassone-Corsi, P.,
Mizzen, C. A.,
Cheung, P.,
Crosio, C.,
Monaco, L.,
Jacquot, S.,
Hanauer, A.,
and Allis, C. D.
(1999)
Science
285,
886-891 |
| 12. |
Wei, Y., Yu, L.,
Bowen, J.,
Gorovsky, M. A.,
and Allis, C. D.
(1999)
Cell
97,
99-109[CrossRef][Medline]
[Order article via Infotrieve] |
| 13. |
Wang, H.,
Huang, Z. Q.,
Xia, L.,
Feng, Q.,
Erdjument-Bromage, H.,
Strahl, B. D.,
Briggs, S. D.,
Allis, C. D.,
Wong, J.,
Tempst, P.,
and Zhang, Y.
(2001)
Science
293,
853-857 |
| 14. |
Zhang, Y.,
and Reinberg, D.
(2001)
Genes Dev.
15,
2343-2360 |
| 15. |
Rea, S.,
Eisenhaber, F.,
O'Carroll, D.,
Strahl, B. D.,
Sun, Z. W.,
Schmid, M.,
Opravil, S.,
Mechtler, K.,
Ponting, C. P.,
Allis, C. D.,
and Jenuwein, T.
(2000)
Nature
406,
593-599[CrossRef][Medline]
[Order article via Infotrieve] |
| 16. |
Chen, D., Ma, H.,
Hong, H.,
Koh, S. S.,
Huang, S. M.,
Schurter, B. T.,
Aswad, D. W.,
and Stallcup, M. R.
(1999)
Science
284,
2174-2177 |
| 17. |
Chen, H.,
Lin, R. J.,
Schiltz, R. L.,
Chakravarti, D.,
Nash, A.,
Nagy, L.,
Privalsky, M. L.,
Nakatani, Y.,
and Evans, R. M.
(1997)
Cell
90,
569-580[CrossRef][Medline]
[Order article via Infotrieve] |
| 18. |
Ogryzko, V. V.,
Schiltz, R. L.,
Russanova, V.,
Howard, B. H.,
and Nakatani, Y.
(1996)
Cell
87,
953-959[CrossRef][Medline]
[Order article via Infotrieve] |
| 19. |
Yang, X. J.,
Ogryzko, V. V.,
Nishikawa, J.,
Howard, B. H.,
and Nakatani, Y.
(1996)
Nature
382,
319-324[CrossRef][Medline]
[Order article via Infotrieve] |
| 20. |
Kawasaki, H.,
Schiltz, L.,
Chiu, R.,
Itakura, K.,
Taira, K.,
Nakatani, Y.,
and Yokoyama, K. K.
(2000)
Nature
405,
195-200[CrossRef][Medline]
[Order article via Infotrieve] |
| 21. |
Ait-Si-Ali, S.,
Ramirez, S.,
Barre, F. X.,
Dkhissi, F.,
Magnaghi-Jaulin, L.,
Girault, J. A.,
Robin, P.,
Knibiehler, M.,
Pritchard, L. L.,
Ducommun, B.,
Trouche, D.,
and Harel-Bellan, A.
(1998)
Nature
396,
184-186[CrossRef][Medline]
[Order article via Infotrieve] |
| 22. |
Chakravarti, D.,
Ogryzko, V.,
Kao, H. Y.,
Nash, A.,
Chen, H.,
Nakatani, Y.,
and Evans, R. M.
(1999)
Cell
96,
393-403[CrossRef][Medline]
[Order article via Infotrieve] |
| 23. |
Creaven, M.,
Hans, F.,
Mutskov, V.,
Col, E.,
Caron, C.,
Dimitrov, S.,
and Khochbin, S.
(1999)
Biochemistry
38,
8826-8830[CrossRef][Medline]
[Order article via Infotrieve] |
| 24. |
Barlev, N. A.,
Poltoratsky, V.,
Owen-Hughes, T.,
Ying, C.,
Liu, L.,
Workman, J. L.,
and Berger, S. L.
(1998)
Mol. Cell. Biol.
18,
1349-1358 |
| 25. |
Hamamori, Y.,
Sartorelli, V.,
Ogryzko, V.,
Puri, P. L., Wu, H. Y.,
Wang, J. Y.,
Nakatani, Y.,
and Kedes, L.
(1999)
Cell
96,
405-413[CrossRef][Medline]
[Order article via Infotrieve] |
| 26. |
Wang, L.,
Liu, L.,
and Berger, S. L.
(1998)
Genes Dev.
12,
640-653 |
| 27. |
Zhang, Q., Vo, N.,
and Goodman, R. H.
(2000)
Mol. Cell. Biol.
20,
4970-4978 |
| 28. |
Chen, H.,
Lin, R. J.,
Xie, W.,
Wilpitz, D.,
and Evans, R. M.
(1999)
Cell
98,
675-686[CrossRef][Medline]
[Order article via Infotrieve] |
| 29. |
Vaesen, M.,
Barnikol-Watanabe, S.,
Gotz, H.,
Awni, L. A.,
Cole, T.,
Zimmermann, B.,
Kratzin, H. D.,
and Hilschmann, N.
(1994)
Biol. Chem. Hoppe-Seyler
375,
113-126[Medline]
[Order article via Infotrieve] |
| 30. |
Chen, T. H.,
Brody, J. R.,
Romantsev, F. E., Yu, J. G.,
Kayler, A. E.,
Voneiff, E.,
Kuhajda, F. P.,
and Pasternack, G. R.
(1996)
Mol. Biol. Cell
7,
2045-2056[Abstract] |
| 31. |
Matsuoka, K.,
Taoka, M.,
Satozawa, N.,
Nakayama, H.,
Ichimura, T.,
Takahashi, N.,
Yamakuni, T.,
Song, S. Y.,
and Isobe, T.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
9670-9674 |
| 32. |
Mencinger, M.,
Panagopoulos, I.,
Contreras, J. A.,
Mitelman, F.,
and Aman, P.
(1998)
Biochim. Biophys. Acta
1395,
176-180[Medline]
[Order article via Infotrieve] |
| 33. |
Ulitzur, N.,
Humbert, M.,
and Pfeffer, S. R.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
5084-5089 |
| 34. |
Brennan, C. M.,
Gallouzi, I. E.,
and Steitz, J. A.
(2000)
J. Cell Biol.
151,
1-14 |
| 35. |
Matilla, A.,
Koshy, B. T.,
Cummings, C. J.,
Isobe, T.,
Orr, H. T.,
and Zoghbi, H. Y.
(1997)
Nature
389,
974-978[CrossRef][Medline]
[Order article via Infotrieve] |
| 36. |
Brody, J. R.,
Kadkol, S. S.,
Mahmoud, M. A.,
Rebel, J. M.,
and Pasternack, G. R.
(1999)
J. Biol. Chem.
274,
20053-20055 |
| 37. |
Matsumoto, K.,
Nagata, K.,
Okuwaki, M.,
and Tsujimoto, M.
(1999)
FEBS Lett.
463,
285-288[CrossRef][Medline]
[Order article via Infotrieve] |
| 38. |
Martinez-Balbas, M. A.,
Bannister, A. J.,
Martin, K.,
Haus-Seuffert, P.,
Meisterernst, M.,
and Kouzarides, T.
(1998)
EMBO J.
17,
2886-2893[CrossRef][Medline]
[Order article via Infotrieve] |
| 39. |
Malek, S. N.,
Katumuluwa, A. I.,
and Pasternack, G. R.
(1990)
J. Biol. Chem.
265,
13400-13409 |
| 40. |
Li, M.,
Makkinje, A.,
and Damuni, Z.
(1996)
Biochemistry
35,
6998-7002[CrossRef][Medline]
[Order article via Infotrieve] |
| 41. |
Matsumoto, K.,
Nagata, K., Ui, M.,
and Hanaoka, F.
(1993)
J. Biol. Chem.
268,
10582-10587 |
This article has been cited by other articles:
![]() |
S. Chen, B. Li, I. Grundke-Iqbal, and K. Iqbal I PP2A 1 Affects Tau Phosphorylation via Association with the Catalytic Subunit of Protein Phosphatase 2A J. Biol. Chem., April 18, 2008; 283(16): 10513 - 10521. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Munemasa, T. Suzuki, K. Aizawa, S. Miyamoto, Y. Imai, T. Matsumura, M. Horikoshi, and R. Nagai Promoter Region-Specific Histone Incorporation by the Novel Histone Chaperone ANP32B and DNA-Binding Factor KLF5 Mol. Cell. Biol., February 1, 2008; 28(3): 1171 - 1181. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Huyton and C. Wolberger The crystal structure of the tumor suppressor protein pp32 (Anp32a): Structural insights into Anp32 family of proteins Protein Sci., July 1, 2007; 16(7): 1308 - 1315. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Muto, M. Senda, Y. Akai, L. Sato, T. Suzuki, R. Nagai, T. Senda, and M. Horikoshi Relationship between the structure of SET/TAF-Ibeta/INHAT and its histone chaperone activity PNAS, March 13, 2007; 104(11): 4285 - 4290. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. O. Evert, J. Araujo, A. M. Vieira-Saecker, R. A. I. de Vos, S. Harendza, T. Klockgether, and U. Wullner Ataxin-3 Represses Transcription via Chromatin Binding, Interaction with Histone Deacetylase 3, and Histone Deacetylation. J. Neurosci., November 1, 2006; 26(44): 11474 - 11486. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. T. Schafer, A. B. Parrish, K. M. Wright, S. S. Margolis, J. R. Marks, M. Deshmukh, and S. Kornbluth Enhanced Sensitivity to Cytochrome c-Induced Apoptosis Mediated by PHAPI in Breast Cancer Cells Cancer Res., February 15, 2006; 66(4): 2210 - 2218. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. H.C. Dirksen, J. Cloos, B. J.M. Braakhuis, R. H. Brakenhoff, A. J.R. Heck, and M. Slijper Human Lymphoblastoid Proteome Analysis Reveals a Role for the Inhibitor of Acetyltransferases Complex in DNA Double-Strand Break Response Cancer Res., February 1, 2006; 66(3): 1473 - 1480. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Macfarlan, J. B. Parker, K. Nagata, and D. Chakravarti Thanatos-Associated Protein 7 Associates with Template Activating Factor-I{beta} and Inhibits Histone Acetylation to Repress Transcription Mol. Endocrinol., February 1, 2006; 20(2): 335 - 347. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Hublitz, N. Kunowska, U. P. Mayer, J. M. Muller, K. Heyne, N. Yin, C. Fritzsche, C. Poli, L. Miguet, I. W. Schupp, et al. NIR is a novel INHAT repressor that modulates the transcriptional activity of p53 Genes & Dev., December 1, 2005; 19(23): 2912 - 2924. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Macfarlan, S. Kutney, B. Altman, R. Montross, J. Yu, and D. Chakravarti Human THAP7 Is a Chromatin-associated, Histone Tail-binding Protein That Represses Transcription via Recruitment of HDAC3 and Nuclear Hormone Receptor Corepressor J. Biol. Chem., February 25, 2005; 280(8): 7346 - 7358. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Xue, J. S. Johnson, D. A. Ornelles, J. Lieberman, and D. A. Engel Adenovirus Protein VII Functions throughout Early Phase and Interacts with Cellular Proteins SET and pp32 J. Virol., February 15, 2005; 79(4): 2474 - 2483. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. B. Choi, J. K. Ko, and J. Shin The Transcriptional Corepressor, PELP1, Recruits HDAC2 and Masks Histones Using Two Separate Domains J. Biol. Chem., December 3, 2004; 279(49): 50930 - 50941. [Abstract] [Full Text] [PDF] |